A new oral delivery system for 5-ASA: preliminary clinical findings for MMx.
about
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitisRectal 5-aminosalicylic acid for induction of remission in ulcerative colitisOral 5-aminosalicylic acid for induction of remission in ulcerative colitisBudesonide Multi-matrix for the Treatment of Patients with Ulcerative ColitisMulti-matrix system mesalamine: to use or not to use.Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis.Emerging drugs for the treatment of ulcerative colitisWhat's new: innovative concepts in inflammatory bowel disease.Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis.Update in the treatment of paediatric ulcerative colitis.The role of mesalamine in the treatment of ulcerative colitis.Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis.Quality of life of patients with ulcerative colitis: past, present, and future.MMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitis.Preventing recurrent acute diverticulitis with pharmacological therapiesMesalamine with MMX technology for the treatment of ulcerative colitis.Patient considerations in the management of ulcerative colitis: role of once-daily MMX mesalamine.Adherence in ulcerative colitis: an overview.Insight into the widespread problem of nonadherence to therapy in ulcerative colitis patients.Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis.Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in Ulcerative Colitis: systematic review and meta-analysis.High mucosal healing rates in 5-ASA-treated ulcerative colitis patients: results of a meta-analysis of clinical trials.Strategies of targeting oral drug delivery systems to the colon and their potential use for the treatment of colorectal cancer.Multi-Matrix System (MMX®) mesalamine for the treatment of mild-to-moderate ulcerative colitis.Recent developments in the treatment of inflammatory bowel disease.Mesalazine for the treatment of inflammatory bowel disease.Novel extended release budesonide formulation for treatment of ulcerative colitis.The role of Budesonide-MMX in active ulcerative colitis.Nanotechnology in the treatment of inflammatory bowel diseases.Low bioavailability steroids in inflammatory bowel disease: an old chestnut or a whole new ballgame?Drug therapies for ulcerative proctitis: systematic review and meta-analysis.Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis.5-Aminosalicylic acid, a specific drug for ulcerative colitis.The long journey of salicylates in ulcerative colitis: The past and the future.Review article: the histological assessment of disease activity in ulcerative colitis.The problem of adherence to therapy in ulcerative colitis and the potential utility of multi-matrix system (MMX) technology.MMX® technology and its applications in gastrointestinal diseases.Adherence to Rectal Mesalamine in Patients with Ulcerative Colitis.Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel diseaseOptimizing use of 5-ASA in the treatment of ulcerative colitis: Focus on patient compliance and adherence.
P2860
Q24198024-A9A6EC60-2724-4F68-8216-BB8DB93470A3Q24240567-33276803-782C-4DD6-88CA-630712ACF86CQ24246220-37C94009-72AD-4A19-A865-59C43984D442Q26779042-41218280-F42C-4F08-ABC9-9A711B631C28Q33438982-BA75966E-3597-483A-AA8F-27927CC9C9C6Q34273329-03744D5A-329C-4EA0-A1BF-3D04FDA66E10Q36039436-6965E8F0-C318-4A7A-AC75-ACD1D812C597Q36440535-7A931362-5DBC-4AB0-8632-CB32A99DF1CDQ36555966-DEAD52EC-77CD-4956-98E2-01EFF03D7C9DQ36613876-86B1ED3D-94A7-4288-B8D4-C1FAFB8A54F6Q36645826-B42D968D-FAEC-4B6C-930A-FAFED73FFC25Q36930800-E921A37B-EE66-4F24-8D8D-1C576F2CBA0CQ36987080-A316ACB0-7DE6-4DED-BC6E-668B18EEC613Q37123430-C1204840-B806-40C7-870D-66AB23BCD3B1Q37253907-CC264D09-A0F8-491C-9058-BF65C01C9D6BQ37345925-4007C794-5F0B-4198-A8F6-A292654DB575Q37423752-8F58DFE4-6707-47F6-9C83-2CCF8EC7945DQ37669367-34A6BFD7-B6B4-48AD-BCA9-25D636752D95Q37769255-8E22B015-8199-401A-848F-3ACDAFFC422CQ37850826-E5CA605D-54D9-428F-87E6-6DA4157E5595Q37959710-C3223660-3779-4514-9A6F-938E786FCB2CQ37993821-FE87FD41-C70A-489F-8E35-109BA57A8B39Q38017299-7AA4A24D-FE07-4BEC-860E-B9E1B594EDFBQ38042702-D385F766-E116-4D85-B7C7-104FEDAA3A4FQ38082550-DB9B688D-DE2B-4EA7-AE57-3EBB18172061Q38114476-E0E8F7CD-1C64-4C55-8B9F-CDB20E25F198Q38161988-66574D77-0F2E-4D92-910B-A92FF60707E2Q38185703-AA689042-400B-4B72-92E8-28687F23CB81Q38200842-ABEA5E7D-01E7-4D32-A139-A495E39CCEC8Q38216510-339F8479-BBAA-467E-9FB2-6872D5E902A5Q38235056-6B31A6F4-F64A-4B1D-AD60-8367E7C3DBE6Q38288749-D2061B15-0361-403B-985C-43089501CF86Q38367034-70C0634B-F5A9-4FC8-9D9F-72424FD8F7D7Q38571119-B15ECDFF-CAA9-4251-A702-7B859DA15569Q38573248-BD115257-7F96-44DD-BEE6-EF1C1224E533Q38996677-7377CA33-A048-4916-A575-0CC817FAD1E9Q40095211-8C1EAE0A-3CA9-4218-B87B-FCE8D53BBA2DQ40600605-FE204309-29CB-44F4-8DCB-B4F5B223E3CFQ41891210-BEB09574-8622-46F3-9D0C-8899F5E3CF7FQ42273744-5A70BBAA-EE02-48B4-BAC1-F7BA49DA0897
P2860
A new oral delivery system for 5-ASA: preliminary clinical findings for MMx.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
A new oral delivery system for 5-ASA: preliminary clinical findings for MMx.
@en
A new oral delivery system for 5-ASA: preliminary clinical findings for MMx.
@nl
type
label
A new oral delivery system for 5-ASA: preliminary clinical findings for MMx.
@en
A new oral delivery system for 5-ASA: preliminary clinical findings for MMx.
@nl
prefLabel
A new oral delivery system for 5-ASA: preliminary clinical findings for MMx.
@en
A new oral delivery system for 5-ASA: preliminary clinical findings for MMx.
@nl
P2093
P2860
P1476
A new oral delivery system for 5-ASA: preliminary clinical findings for MMx
@en
P2093
Antonio Francavilla
Cosimo Prantera
Livia Biancone
Lucio Giglio
P2860
P304
P356
10.1097/01.MIB.0000158386.25660.1E
P577
2005-05-01T00:00:00Z